NCT04735510View on ClinicalTrials.gov

Novel Use of Restasis and PROSE Devices

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 31, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

Ocular Surface Disease

Interventions

DRUG

cyclosporine ophthalmic emulsion 0.05%

All subjects will receive restasis

Trial Locations (1)

02494

BostonSight, Needham

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Boston Sight

OTHER